These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 3297316)

  • 21. [L-threo-DOPS therapy and parkinsonism].
    Narabayashi H
    No To Shinkei; 1986 Jan; 38(1):60-2. PubMed ID: 3083844
    [No Abstract]   [Full Text] [Related]  

  • 22. The genetics of Parkinson's disease: a reconsideration.
    Golbe LI
    Neurology; 1990 Oct; 40(10 Suppl 3):suppl 7-14; discussion 14-6. PubMed ID: 2215974
    [No Abstract]   [Full Text] [Related]  

  • 23. MPTP-induced parkinsonism. Recent studies on the mechanism of toxicity.
    Bocchetta A; Piccardi MP; Zuddas A; Bernardi F; Zompo MD; Corsini GU
    Funct Neurol; 1988; 3(4):439-47. PubMed ID: 3072279
    [No Abstract]   [Full Text] [Related]  

  • 24. [Experimental model of Parkinson disease induced by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Renkawek K
    Neuropatol Pol; 1986; 24(1):1-8. PubMed ID: 3489205
    [No Abstract]   [Full Text] [Related]  

  • 25. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [MPTP parkinsonism].
    Kondo T
    Ryoikibetsu Shokogun Shirizu; 1999; (27 Pt 2):37-40. PubMed ID: 10434585
    [No Abstract]   [Full Text] [Related]  

  • 27. MPTP toxicity: clinical features.
    Williams A
    J Neural Transm Suppl; 1986; 20():5-9. PubMed ID: 3489070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) and parkinsonism].
    Gao XM; Ku BS
    Sheng Li Ke Xue Jin Zhan; 1989 Apr; 20(2):161-3. PubMed ID: 2686017
    [No Abstract]   [Full Text] [Related]  

  • 29. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease.
    Langston JW; Ballard P
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):160-5. PubMed ID: 6608979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The MPTP story: an introduction.
    Marsden CD; Sandler M
    J Neural Transm Suppl; 1986; 20():1-3. PubMed ID: 3091759
    [No Abstract]   [Full Text] [Related]  

  • 31. Changes in the local cerebral metabolic rate for glucose in the MPTP primate model of Parkinson's disease.
    Schwartzman RJ; Alexander GM
    Adv Neurol; 1987; 45():171-3. PubMed ID: 3493624
    [No Abstract]   [Full Text] [Related]  

  • 32. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MPTP: current concepts and controversies.
    Langston JW; Irwin I
    Clin Neuropharmacol; 1986; 9(6):485-507. PubMed ID: 3542203
    [No Abstract]   [Full Text] [Related]  

  • 34. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases.
    Ballard PA; Tetrud JW; Langston JW
    Neurology; 1985 Jul; 35(7):949-56. PubMed ID: 3874373
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saccade responses to dopamine in human MPTP-induced parkinsonism.
    Hotson JR; Langston EB; Langston JW
    Ann Neurol; 1986 Oct; 20(4):456-63. PubMed ID: 3491578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of increasing regimens of levodopa on chronic MPTP-induced parkinsonism in monkey; mechanographic and electromyographic data.
    Doudet D; Gross C; Lebrun-Grandie P; Bioulac B
    Electromyogr Clin Neurophysiol; 1986 Dec; 26(8):711-27. PubMed ID: 3493894
    [No Abstract]   [Full Text] [Related]  

  • 37. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA; Neafsey EJ; Cheng BY; Hurley-Gius K; Ung-Chhun NA; Pronger DA; Christensen MA; Hurley-Gius D
    Adv Neurol; 1987; 45():179-82. PubMed ID: 3493625
    [No Abstract]   [Full Text] [Related]  

  • 38. Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.
    Herrero MT; Levy R; Ruberg M; Javoy-Agid F; Luquin MR; Agid Y; Hirsch EC; Obeso JA
    Adv Neurol; 1996; 69():209-16. PubMed ID: 8615130
    [No Abstract]   [Full Text] [Related]  

  • 39. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neuroleptic-induced parkinsonism and Parkinson's disease: differential diagnosis and treatment.
    Hausner RS
    J Clin Psychiatry; 1983 Jan; 44(1):13-6. PubMed ID: 6130081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.